Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
Gespeichert in:
Verfasser / Beitragende:
[David Rossi, Donatella Dennetta, Marcello Ugolini, Vincenzo Catalano, Paolo Alessandroni, Paolo Giordani, Anna Baldelli, Virginia Casadei, Francesco Graziano, S. Luzi Fedeli]
Ort, Verlag, Jahr:
2010
Enthalten in:
Targeted Oncology, 5/4(2010-12-01), 231-235
Format:
Artikel (online)
Online Zugang: